Pharmaceuticals, Biotechnology and Life Sciences
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by…
CARLSBAD, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and…
– Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month…
45 percent reduction in risk of death achieved with cilta-cel versus standard therapies after three-year follow-up in landmark CARTITUDE-4 study1…
Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year follow-upLate-breaking data featured in…
Affluent Medical, a French clinical-stage medical technology company specializing in the international development and industrialization of implantable innovative medical devices, reported a net loss of €9.4 million in H1 2024, compared to a net loss of €8.0 million in the prior year period, citing several majors steps developing its three medical devices.
ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified…
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company…
DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,…
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024,…